Outlook Therapeutics (OTLK) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
26 Jan, 2026Voting matters and shareholder proposals
Election of three directors: Faisal G. Sukthian, Yezan Haddadin, and Kurt J. Hilzinger, with board recommending a vote for each.
Ratification of KPMG LLP as the independent registered public accounting firm for fiscal year 2026.
Non-binding advisory vote on the compensation of named executive officers, with board recommending approval.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends all director nominees for election at the annual meeting.
Executive compensation and say-on-pay
Shareholders will vote on a non-binding advisory resolution regarding executive officer compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Outlook Therapeutics
- FDA-approved LYTENAVA targets $500M+ U.S. peak sales by 2030, with launch funding secured.OTLK
Q3 2026 - Resale registration for 17.26M shares linked to warrants, targeting major retina drug markets.OTLK
Registration filing - Shareholders are asked to approve a reverse stock split to maintain Nasdaq listing compliance.OTLK
Proxy filing - Approval sought for new share issuances, share increase, and reverse split to maintain Nasdaq listing.OTLK
Proxy filing - Key votes include new share issuances, a major increase in authorized shares, and a reverse split.OTLK
Proxy filing - Votes sought on new share issuances, share increase, and reverse split to maintain Nasdaq listing.OTLK
Proxy filing - Net loss of $27.5M, negative revenue, and urgent funding needs as FDA approval remains pending.OTLK
Q2 2026 - Net loss of $23.1M, negative revenue, and liquidity risks as US approval remains uncertain.OTLK
Q1 2026 - EU/UK approvals achieved; 2025 launches planned, but going concern risk persists.OTLK
Q3 2024